Ketryx, the agentic continuous compliance platform for safety-critical product development, announced today that William A. Hawkins, former Chairman and CEO of Medtronic, has joined its Board of Directors. Hawkins also participated in the company's Series B financing, underscoring his commitment to the firm's mission.
Ketryx helps companies in safety-critical industries—including medical devices, pharmaceuticals, and robotics—accelerate product development by automatically generating compliant documentation, maintaining continuous traceability, and enabling safe and verifiable AI at scale within the tools teams already use. The company's platform overlays existing development tools to automate documentation, create traceability, and accelerate release cycles without disrupting workflows. Ketryx AI Agents reduce manual work by up to 90 percent and help teams identify and close compliance gaps.
Hawkins brings decades of leadership experience in the medical device industry. As CEO of Medtronic from 2007 to 2011, he oversaw significant growth and innovation. His appointment to Ketryx's board signals strong industry endorsement for the company's approach to solving compliance bottlenecks that slow down product development in regulated environments.
The partnership comes at a critical time when life sciences companies are under pressure to bring products to market faster while maintaining rigorous regulatory standards. Ketryx's platform directly addresses the challenge of integrating AI into safety-critical workflows without compromising compliance. By automating the tedious aspects of documentation and traceability, the platform enables teams to focus on innovation.
Ketryx is trusted by four of the world's top five medical device manufacturers. The company's technology is designed to work seamlessly with existing tools, making it easier for organizations to adopt without overhauling their current systems. For more information, visit www.ketryx.com.
The addition of Hawkins to the board is expected to accelerate Ketryx's growth and market adoption. His experience in scaling a global medical device leader will be invaluable as Ketryx expands its footprint in the life sciences sector. The company's Series B financing round, which Hawkins participated in, will support further product development and market expansion.
Ketryx's platform represents a significant advancement in how safety-critical industries approach product development and compliance. By leveraging AI to automate compliance tasks, companies can reduce time-to-market while maintaining the highest safety standards. This is particularly important as regulatory bodies increasingly scrutinize the use of AI in medical devices and pharmaceuticals.
With Hawkins on board, Ketryx is well-positioned to solve the AI bottleneck in life sciences, enabling faster, safer product development. The company's innovative approach to continuous compliance is set to transform the industry, making it easier for companies to deliver life-saving products to patients in need.
